Other OTC - Delayed Quote • USD
Sorrento Therapeutics, Inc. (SRNE)
At close: 3:56 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -0.54 | -0.2 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 1 |
| Avg. Estimate | 22.6M | 23.2M | 57.53M | 210.65M |
| Low Estimate | 22.6M | 23.2M | 24.65M | 210.65M |
| High Estimate | 22.6M | 23.2M | 90.4M | 210.65M |
| Year Ago Sales | 11.46M | 17.4M | 62.84M | 57.53M |
| Sales Growth (year/est) | 97.20% | 33.30% | -8.40% | 266.20% |
Earnings History
| CURRENCY IN USD | 6/30/2022 | 9/30/2022 | 12/31/2022 | 3/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.25 | -0.19 | -0.16 |
| EPS Actual | -0.54 | -0.2 | -0.46 | -0.26 |
| Difference | -0.29 | 0.05 | -0.27 | -0.1 |
| Surprise % | -116.00% | 20.00% | -142.10% | -62.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -0.15 | -0.15 | -0.68 | -0.33 |
| 30 Days Ago | -0.15 | -0.15 | -0.68 | -0.33 |
| 60 Days Ago | -0.15 | -0.15 | -0.68 | -0.33 |
| 90 Days Ago | -0.15 | -0.15 | -0.68 | -0.33 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2023) | Next Qtr. (Sep 2023) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SRNE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.60% |
| Next Qtr. | -- | -- | -- | 10.50% |
| Current Year | -- | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | 37.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Related Tickers
SNGX Soligenix, Inc.
0.4310
-0.99%
LGVN Longeveron Inc.
1.9200
-4.48%
INO Inovio Pharmaceuticals, Inc.
9.68
-5.10%
MRNS Marinus Pharmaceuticals, Inc.
1.3800
-2.13%
ONVO Organovo Holdings, Inc.
1.1000
-4.35%
PXMD PaxMedica, Inc.
0.7609
-0.29%
CELU Celularity Inc.
3.0300
-5.61%
JAGX Jaguar Health, Inc.
0.1569
-11.41%
ALLR Allarity Therapeutics, Inc.
1.3900
-9.74%
RLYB Rallybio Corporation
1.7600
+5.39%